In the next-to-last line on page 1792, “frontline” should be deleted. In the third line under “Fedratinib approval and clinical utilization implications” on page 1796, “(NCT03755518, frontline; NCT03952039, second line)” should read, “(NCT03755518 and the second-line NCT03952039).” In the second and third lines of the right column of page 1798, “a frontline trial for additional safety data” should read “an efficacy and safety trial of fedratinib in myelofibrosis previously treated with ruxolitinib.” The errors have been corrected in the published article.
© 2020 by The American Society of Hematology
2020
